Skip to content
Review Open access

Emerging Markers in Osteoporosis, A Review

Aug 2026 · AL-Kindy College Medical Journal · 0 citations · 110 references

TL;DR

Existing and novel Osteoporosis biomarkers, their mechanisms, clinical efficacy, drawbacks, and the best biomarkers in Osteoporosis risk stratification and management are discussed, to convert them into better patient care.

Abstract

Osteoporosis is a global health concern with bone frailty and high fracture risk. Existing diagnostic paradigms largely rely on bone scanning and bone mineral density evaluation which are hindered by the delayed prediction of fractures, especially in high-risk groups. This review assesses existing and novel Osteoporosis biomarkers, their mechanisms, clinical efficacy, drawbacks, and discusses the best biomarkers in Osteoporosis risk stratification and management, to convert them into better patient care. An online search was conducted, including PubMed, Web of Science, Embase, and Google Scholar up to June 2026. Passed studies were reviewed critically and organized biomarkers into five different panels: traditional and bone turnover markers, mineral metabolism and endocrine regulators, inflammatory and immune mediators, novel metabolic and multi-omics biomarkers, and combined biomarker panels. The traditional markers are still useful in therapeutic monitoring, although they have a natural biological variability that cannot be used to achieve optimum diagnostic use. Combined and inflammatory mediator panels showed greater discriminative ability, with Net Reclassification Index improvements of 0.15-0.23, appropriately reclassifying 15-23 percent of intermediate-risk patients who were misidentified by traditional screening. The highest performance acquisition was experienced in diabetic cohorts, where density-based measurements often miss. The management of osteoporosis should be changed to precision medicine with multi-dimensional biochemical profiling. The clinical utility and cost-effectiveness of the integrated approach in biomarkers make them a mandatory complement to imaging and a crucial point in holistic patient care for improved prognosis.

Read PDF

Similar papers

Review Open access Aug 2026

Clinical Significance of Bone Turnover Markers in Osteoporosis: Fracture Risk Assessment and Treatment Monitoring.

Osteoporosis is a systemic skeletal disorder characterized by compromised bone strength and a higher risk of fractures. Although bone mineral density (BMD) remains the primary diagnostic measure, it has several limitations, including delayed detection of therapeutic response, restricted measurement sites, and limited sensitivity to predict fracture risk accurately. Bone turnover markers (BTMs) are noninvasive indicators of bone remodeling that are increasingly being used as complementary tools in osteoporosis assessment. Among them, serum procollagen type I N-terminal propeptide and C-terminal telopeptide of type I collagen are reference markers of bone formation and resorption. However, BTM levels can be influenced by biological and pathological factors, including circadian rhythms, food intake, and assay variability, thereby limiting their routine use as predictive markers. In individuals at risk of fracture, antiresorptive agents such as bisphosphonates and denosumab cause rapid alterations in BTMs, which correlate with long-term gains in BMD and reduced fracture risk. Monitoring BTMs can help evaluate therapeutic efficacy and adherence and complement BMD measurement in fracture risk prediction. Overall, rather than being used as stand-alone diagnostic markers, BTMs should be used as complementary tools for monitoring therapeutic responses and supporting fracture risk assessment.

N. Kim, Y. Chung, S. Seo · 0 citations
Review Open access May 2026

Male osteoporosis: pathophysiology, risk assessment, and evidence-based management

Effective care in cases of male osteoporosis requires an integrated risk-based approach that extends beyond BMD to include clinical risk factors, secondary causes, and functional status, and improved recognition and sex-specific management strategies are essential to reduce the fracture burden and improve long-term outcomes in men.

Selin Tekin, A. Gürlek · 0 citations
Review Open access Jul 2026

Endocrine-related osteoporosis: bone quality, clinical phenotype, and targeted management

A practical clinical framework is proposed that integrates endocrine phenotype, vertebral imaging, trabecular bone score, and biochemical assessment into fracture-risk stratification and therapeutic decision-making, enabling improved identification of high- and very-high-risk patients and facilitating the appropriate use of anabolic and antiresorptive therapies.

I. Cincione, Robert A. Marcantonio, Marcellino Monda et al. · 0 citations
Review Open access Sep 2026

Osteoporosis Diagnosis and Management: A Review from an Orthopedic Perspective

This review synthesizes international guidelines and recent literature to provide a practical framework for DEXA interpretation, laboratory integration, and holistic management aimed at reducing refracture risk, improving functional outcomes, and lowering healthcare costs.

Jee-Young Lee, Se Lim Kim, G. Kong · 0 citations
Open access Aug 2026

Endocrine and metabolic determinants of CKD-associated osteoporosis: diagnostic insights and clinical implications

Results indicate that radiofrequency echographic multispectrometry provides BMD and fracture risk assessment comparable to DXA in patients on peritoneal dialysis, while also highlighting the impact of vascular calcifications on the diagnostic accuracy of lumbar spine DXA measurements.

O. I. Nishkumay, O. B. Iaremenko, V. Kondratiuk et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.